Novartis' nilotinib (AMN107, trade name Tasigna)
The drug, already approved by the FDA for cancer treatment, improved cognition, motor skills and non-motor function in patients with Parkinson's disease, the university researchers reported.
Note: earlier/sooner FDA approval as it is existing drug
"To my knowledge, this study represents the first time
The drug, already approved by the FDA for cancer treatment, improved cognition, motor skills and non-motor function in patients with Parkinson's disease, the university researchers reported.
Note: earlier/sooner FDA approval as it is existing drug
"To my knowledge, this study represents the first time